Oncology

HLX02, Pertuzumab, Chemotherapy Combination Effective, Safe in Advanced HER2-Positive Breast Cancer

March 12th 2024

By Cameron Santoro

A study found combining trastuzumab biosimilar HLX02, pertuzumab, and chemotherapy was effective and safe for patients with HER2-positive metastatic breast cancer who progressed after prior trastuzumab therapy.

The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability

March 11th 2024

By Kashyap Patel, MD

Article

Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.

Bevacizumab Biosimilars Offer Promise for CRC Treatment, Wound Healing, and Cost Savings

February 28th 2024

By Skylar Jeremias

Article

A review emphasizes that bevacizumab biosimilars demonstrate comparable efficacy to the reference product (Avastin) in the treatment of colorectal cancer (CRC) by tackling wound healing concerns in anorectal medicine.

Eye on Pharma: Celltrion Biosimilars Win Tenders; Oral Ustekinumab Device Passes Phase 1 Trial

February 12th 2024

By Skylar Jeremias

Article

Celltrion announced that 3 of its oncology biosimilar products have won tender contracts in France and Italy, and an experimental oral delivery device utilizing an ustekinumab biosimilar was successful in a phase 1 study.

Analyzing Safety of Switching From Originators to Biosimilars: A Meta-Analysis of 21 Trials

February 10th 2024

By Deana Ferreri, PhD

Article

The authors of a meta-analysis assessing several disease states found no significant differences in serious adverse events, deaths, or treatment discontinuations between patients who switched from reference products to biosimilars and those who did not.

Vizient Report Emphasizes Biosimilar Successes, Impact of Inflation on Drug Spend

February 7th 2024

By Skylar Jeremias

Article

Vizient’s most recent Pharmacy Market Outlook report showcased the success of biosimilars while also emphasizing the impact of inflation on different drug classes, particularly in oncology and immunology.

Report: Varied Biosimilar Uptake Speeds Pose Missed Opportunities for Cost Savings

January 23rd 2024

By Skylar Jeremias

Article

Samsung Bioepis’ Biosimilar Market Report for the first quarter of 2024 chronicles some major market trends, including which treatment spaces have quicker uptake than others, highlighting missed opportunities for savings as well as the 1-year experience of adalimumab biosimilar competition in the US.

Postapproval Pharmacovigilance Review Confirms Comparable Safety Between Sandoz Biosimilars, Originators

January 20th 2024

By Deana Ferreri, PhD

Article

Authors of a review of available postapproval pharmacovigilance data assessing 8 Sandoz biosimilars concluded that these biosimilars “can be used as safely as their respective reference biologics.”

IQVIA Projects $192 Billion Loss for Originators by 2028 Thanks to Biosimilar, Generic Competition

January 18th 2024

By Skylar Jeremias

Article

The IQVIA Institute for Human Data Science’s most recent Global Use of Medicines report projected that market introductions of new biosimilar and generic drugs will increase projected losses for originator products from $111 billion to $192 billion over the next 5 years.

SABCS Posters Review Use of Biosimilars in New Contexts as Breast Cancer Therapy

January 17th 2024

By Skylar Jeremias

Article

As one study presented at the 2023 San Antonio Breast Cancer Symposium (SABCS) evaluated the use of circulating tumor DNA for response prediction after combination therapy with a trastuzumab biosimilar, another examined the efficacy of a pertuzumab biosimilar candidate.